New Horizon Health (čÆŗč¾å„åŗ·) Pre-IPO:Ā Thoughts on Valuation
We value the company's core product, ColoClear at USD 2.6 bn and the company at USD 3.1bn on an SOTP basis. We will also discuss push factor that...
782 Views
ECM Weekly (17 January 2021) - RLX Tech, Kuaishou, PTT Retail, MicroPort CardioFlow, New Horizon
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
819 Views
New Horizon Health IPO: Aiming to Become Pioneer in Cancer Screening
New Horizon Health, the pioneer in Chinaās colorectal cancer screening market has filed for an IPO on the Hong Kong Stock Exchange and the company...
701 Views
New Horizon Health (čÆŗč¾å„åŗ·) Pre-IPO: Comparison with Exact Sciences
We compare the company's product with the benchmark product, Exact Sciences' Cologuard. We think ColoClear is ahead of the Cologuard with...
702 Views
New Horizon Health IPO Initiation: Screening for Cancer
New Horizon will have a listing hearing for a $300 million HK IPO this week. We believe that New Horizon has the right ingredients to capitalise on...
621 Views